Michael A Jacobetz
Overview
Explore the profile of Michael A Jacobetz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
4355
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kultti A, Zhao C, Singha N, Zimmerman S, Osgood R, Symons R, et al.
Biomed Res Int
. 2014 Aug;
2014:817613.
PMID: 25147816
Extensive accumulation of the glycosaminoglycan hyaluronan is found in pancreatic cancer. The role of hyaluronan synthases 2 and 3 (HAS2, 3) was investigated in pancreatic cancer growth and the tumor...
2.
Jacobetz M, Chan D, Neesse A, Bapiro T, Cook N, Frese K, et al.
Gut
. 2012 Apr;
62(1):112-20.
PMID: 22466618
Objective: Pancreatic ductal adenocarcinoma (PDA) is characterised by stromal desmoplasia and vascular dysfunction, which critically impair drug delivery. This study examines the role of an abundant extracellular matrix component, the...
3.
Cook N, Frese K, Bapiro T, Jacobetz M, Gopinathan A, Miller J, et al.
J Exp Med
. 2012 Feb;
209(3):437-44.
PMID: 22351932
Pancreatic ductal adenocarcinoma (PDA) is a highly lethal disease that is refractory to medical intervention. Notch pathway antagonism has been shown to prevent pancreatic preneoplasia progression in mouse models, but...
4.
Bapiro T, Richards F, Goldgraben M, Olive K, Madhu B, Frese K, et al.
Cancer Chemother Pharmacol
. 2011 Mar;
68(5):1243-53.
PMID: 21431415
Purpose: To develop a sensitive analytical method to quantify gemcitabine (2',2'-difluorodeoxycytidine, dFdC) and its metabolites 2',2'-difluorodeoxyuridine (dFdU) and 2',2'-difluorodeoxycytidine-5'-triphosphate (dFdCTP) simultaneously from tumour tissue. Methods: Pancreatic ductal adenocarcinoma tumour tissue...
5.
Olive K, Jacobetz M, Davidson C, Gopinathan A, McIntyre D, Honess D, et al.
Science
. 2009 May;
324(5933):1457-61.
PMID: 19460966
Pancreatic ductal adenocarcinoma (PDA) is among the most lethal human cancers in part because it is insensitive to many chemotherapeutic drugs. Studying a mouse model of PDA that is refractory...
6.
Flaherty K, Schiller J, Schuchter L, Liu G, Tuveson D, Redlinger M, et al.
Clin Cancer Res
. 2008 Aug;
14(15):4836-42.
PMID: 18676756
Purpose: This study evaluated the safety, maximum tolerated dose, pharmacokinetics, and antitumor activity of sorafenib, a multikinase inhibitor, combined with paclitaxel and carboplatin in patients with solid tumors. Patients And...
7.
Tuveson D, Shaw A, Willis N, Silver D, Jackson E, Chang S, et al.
Cancer Cell
. 2004 Apr;
5(4):375-87.
PMID: 15093544
Activating mutations in the ras oncogene are not considered sufficient to induce abnormal cellular proliferation in the absence of cooperating oncogenes. We demonstrate that the conditional expression of an endogenous...
8.
Hingorani S, Petricoin E, Maitra A, Rajapakse V, King C, Jacobetz M, et al.
Cancer Cell
. 2004 Jan;
4(6):437-50.
PMID: 14706336
To evaluate the role of oncogenic RAS mutations in pancreatic tumorigenesis, we directed endogenous expression of KRAS(G12D) to progenitor cells of the mouse pancreas. We find that physiological levels of...
9.
Hingorani S, Jacobetz M, Robertson G, Herlyn M, Tuveson D
Cancer Res
. 2003 Sep;
63(17):5198-202.
PMID: 14500344
Activating mutations in the BRAF serine/threonine kinase are found in >70% of human melanomas, of which >90% are BRAF(V599E). We sought to investigate the role of the BRAF(V599E) allele in...